Abbott Libre DUO 10 Day: FDA approval for glucose/ketone monitoring

September 26, 2026

Prime Therapeutics – Portal USA

Overview

Abbott Diabetes Care has received FDA approval for its “Libre DUO 10 Day” continuous dual glucose-ketone monitoring system for diabetic patients aged two and older. This device marks the first wearable continuous ketone monitor in the U.S. and the world’s first integrated platform for continuous glucose and ketone monitoring. Clinical trials demonstrated accurate ketone level measurement over a 10-day wear period and early detection of rising ketone levels prior to diabetic ketoacidosis (DKA) onset, promising enhanced safety and proactive management in diabetes care.

In Depth

Key Findings

Abbott Diabetes Care has secured FDA approval for its innovative “Libre DUO 10 Day” continuous dual glucose-ketone monitoring system for diabetic patients aged two and older. This landmark approval establishes the device as the first wearable continuous ketone monitor in the United States and the world’s first single-platform solution for integrated continuous glucose and ketone monitoring.

Technical / Clinical Details

The Libre DUO 10 Day system employs a subcutaneous sensor to continuously measure both glucose and ketone levels in real-time. Clinical trials have validated the device’s ability to accurately measure ketone levels throughout its 10-day wear period. Crucially, it demonstrated efficacy in the early detection of elevated ketone levels, a critical precursor to diabetic ketoacidosis (DKA) onset. This early warning capability is paramount for patients at risk of DKA, particularly those with type 1 diabetes or during periods of illness (sick days) where glucose control can be challenging. Unlike traditional, intermittent ketone testing via urine strips or blood draws, continuous monitoring facilitates timelier intervention, significantly reducing the risk of severe complications.

Background & Context

While continuous glucose monitoring (CGM) has become a standard tool in diabetes management, continuous ketone monitoring has largely been unavailable. Elevated ketones are a direct indicator of DKA, a life-threatening complication if not promptly addressed. Abbott’s new product addresses a significant unmet need by providing a comprehensive, real-time view of both metabolic markers. This integrated approach empowers patients with more complete self-management data and enables healthcare providers to offer more precise and proactive guidance, shifting from reactive treatment to preventative care. The device’s wearable form factor enhances convenience and patient adherence.

Strategic Significance & Outlook

This FDA approval represents a pivotal advancement in personalized diabetes management, extending beyond mere glucose control. It is expected to drive significant growth in the broader continuous monitoring market, potentially spurring competitors to accelerate their own development of integrated glucose-ketone solutions. The innovation promises to improve patient outcomes by enabling earlier detection and intervention for DKA, thereby enhancing safety and quality of life for millions of diabetics globally. Future developments may include advanced AI-driven predictive analytics and even longer-wear sensors, further cementing the role of integrated biosensors in chronic disease management.

Source: https://www.primetherapeutics.com/trending-topics-drug-approvals-september-2026

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.